← Back to Clinical Trials
Recruiting NCT05597891

Endovascular Engineering ENGULF Study

Trial Parameters

Condition Pulmonary Embolism
Sponsor Endovascular Engineering
Study Type INTERVENTIONAL
Phase N/A
Enrollment 181
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2023-01-12
Completion 2025-08-31
Interventions
Hēlo PE Thombectomy System

Brief Summary

Evaluation of initial safety and clinical feasibility of the Hēlo PE Thrombectomy System for thrombectomy in acute submassive pulmonary embolism (PE).

Eligibility Criteria

Asterisks \* indicate entry criteria that can be evaluated during prescreening without obtaining informed consent as they are part of standard of care PE management. Asterisks in parenthesis (\*) indicate entry criteria that can be evaluated during prescreening without obtaining informed consent at Sites that routinely perform CTA as part of standard of care in PE management. Inclusion Criteria: Patients must meet ALL of the following criteria to be eligible for participation in the study: 1. \*Patient is \> 18 and \< 90 years old 2. \*Clinical signs and symptoms consistent with acute submassive PE with duration ≤ 14 days, as determined by the Investigator 3. (\*)CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery) 4. (\*)RV/LV ratio of ≥ 0.9 (Enrollment qualification assessment based on Investigator's interpretation of RV/LV ratio at baseline) 5. \*Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mm

Related Trials